Literature DB >> 6451351

Pharmacokinetic study of different doses of Depo Provera.

K Fotherby, S Koetsawang, M Mathrubutham.   

Abstract

Doses of DepoProvera of 25, 50, 100 and 150mg were administered to four groups of women. The mean time for the return of follicular and luteal activity increased with increasing dose of DepoProvera. Luteal activity was suppressed for a longer period than follicular activity. None of the women receiving the two higher doses of DepoProvera showed a return of luteal function within 100 days of injection. The period for which medroxyprogesterone acetate (MPA) was detectable in serum increased with increasing dose but the values for the 100 and 150mg doses were not significantly different. There was a significant correlation between the concentration of MPA in blood and the return of follicular and luteal function. It is suggested that in the population studied, 100mg DepoProvera would be as effective as the usual 150mg dose and that injection of 50mg DepoProvera would provide a contraceptive effect for two months. The dose of MPA in the monthly injectable CycloProvera could be substantially reduced without loss of effectiveness.

Entities:  

Keywords:  Asia; Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--analysis; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--administraction and dosage; Contraceptive Agents--analysis; Depo-provera--administraction and dosage; Developing Countries; Family Planning; Human Volunteers; Injectables; Medroxyprogesterone Acetate--analysis; Research Methodology; Southeastern Asia; Thailand

Mesh:

Substances:

Year:  1980        PMID: 6451351     DOI: 10.1016/0010-7824(80)90105-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

Review 2.  Injectable contraception with depot medroxyprogesterone acetate. Current status.

Authors:  Andrew M Kaunitz; Allan Rosenfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Facts about injectable contraceptives: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

4.  Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.

Authors:  R Karl Malcolm; Ronald S Veazey; Leslie Geer; Deborah Lowry; Susan M Fetherston; Diarmaid J Murphy; Peter Boyd; Ian Major; Robin J Shattock; Per Johan Klasse; Lara A Doyle; Kelsi K Rasmussen; Laurie Goldman; Thomas J Ketas; John P Moore
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  Interpopulational differences in progesterone levels during conception and implantation in humans.

Authors:  Virginia J Vitzthum; Hilde Spielvogel; Jonathan Thornburg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-02       Impact factor: 11.205

6.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

7.  Reciprocal Modulation of Antiretroviral Drug and Steroid Receptor Function In Vitro.

Authors:  Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 8.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

9.  The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.

Authors:  Roslyn M Ray; Michelle F Maritz; Chanel Avenant; Michele Tomasicchio; Sigcinile Dlamini; Zephne van der Spuy; Janet P Hapgood
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

10.  Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Authors:  Minh Tung Phung; Alice W Lee; Anna H Wu; Andrew Berchuck; Kathleen R Cho; Daniel W Cramer; Jennifer Anne Doherty; Marc T Goodman; Gillian E Hanley; Holly R Harris; Karen McLean; Francesmary Modugno; Kirsten B Moysich; Bhramar Mukherjee; Joellen M Schildkraut; Kathryn L Terry; Linda J Titus; Susan J Jordan; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.